GHRS

GH Research (GHRS)

About GH Research (GHRS)

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Details

Daily high
$15.19
Daily low
$13.96
Price at open
$13.96
52 Week High
$19.51
52 Week Low
$7.98
Market cap
847.3M
Dividend yield
0.00%
Volume
310,168
Avg. volume
270,739
P/E ratio
-18.68

GH Research News

Details

Daily high
$15.19
Daily low
$13.96
Price at open
$13.96
52 Week High
$19.51
52 Week Low
$7.98
Market cap
847.3M
Dividend yield
0.00%
Volume
310,168
Avg. volume
270,739
P/E ratio
-18.68